Malaria, Plasmodium Falciparum Infection
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of L9LS in healthy Malian children, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf) infection over a 7-month malaria season in healthy Malian children 6-10 years of age.
Detailed description
A two-part, phase 2 trial evaluating the safety and tolerability of onetime subcutaneous (SC) or intravenous (IV) administration of monoclonal antibody (MAb) L9LS in healthy Malian adults and one-time SC administration of L9LS in healthy Malian children, as well as its protective efficacy against naturally occurring Plasmodium falciparum (Pf) infection over a 7-month malaria season in healthy Malian children 6-10 years of age. The first part of the study is an age de-escalation and dose-escalation study for safety and tolerability. Adult subjects in the dose-escalation study will be assigned in open-label fashion to 1 of 3 L9LS dose arms. Dosing will begin in the lowest dose arm. Once all subjects in that arm reach day 7 post-administration, if no safety concerns have arisen, dosing will begin at the next dose level. Once all subjects in that arm reach day 7 post-administration, if no safety concerns have arisen, dosing will begin at the highest dose level. Once all adult subjects reach day 7 post-administration, if no safety concerns have arisen, 18 subjects aged 6-10 years will be randomized 1:1 to L9LS or placebo in double-blind fashion. Once all 18 subjects reach day 7 post-administration, if no safety concerns have arisen, an additional 18 subjects aged 6-10 years will be randomized 1:1 to L9LS versus placebo. Randomization of subjects aged 6-10 years in each L9LS dose arm will be weight-stratified and enrollment will be weight de-escalated. Adult subjects will be followed for safety to assess adverse events (AEs) at study visits 1, 3, 7, 14, 21, and 28 days after administration, and once every month thereafter through 28 weeks. Subjects aged 6-10 years will be followed at study visits 1, 3, 7, 14, 21, and 28 days after administration, and once every 2 weeks thereafter through 36 weeks. Primary study assessments include physical examination and blood collection for identification of Pf infection and other research laboratory evaluations. After the last subject in the pediatric L9LS dose arm reaches day 7 safety follow-up, an interim safety evaluation will be performed before enrollment begins for the efficacy part of the study. Data from the 36 subjects aged 6-10 years enrolled in the dose-escalation study will be included in a secondary analysis to determine the relationship between L9LS concentration and the risk of Pf infection. The second part of the study is a weight-stratified, randomized, double-blind, placebo-controlled trial to assess safety and protective efficacy of L9LS versus placebo administered SC in children 6-10 years of age. In this part of the study, subjects will be randomized to L9LS or placebo. Randomization of subjects in each arm will be weight-stratified. Subjects in the efficacy study will receive the study agent prior to the malaria season and be followed at study visits 1, 3, 7, 14, 21, and 28 days later, and once every 2 weeks thereafter through 24 weeks. Primary study assessments include physical examination and blood collection for identification of Pf infection and other research laboratory evaluations. Prior to the last study visit of the original protocol described above (January 2023 - February 2023), study participants who remain enrolled in the dose-escalation and efficacy studies will be invited to participate in a 12-month extension study. After the safety and efficacy results are unblinded (approximately March/April 2023), participants who agree to continue with the extension will be grouped into one of 3 arms based on their original study arm assignment: Arm 1: Up to 84 subjects who received 150 mg of L9LS in year 1 (9 from the dose-escalation study, plus 75 from the efficacy study). Arm 2: Up to 84 subjects who received 300 mg of L9LS in year 1 (9 from the dose-escalation study, plus 75 from the efficacy study). Arm 3: Up to 93 subjects who received placebo in year 1 (18 from the dose-escalation study, plus 75 from the efficacy study). The protocol extension employs a pre-specified, adaptive design based on the time-to-event efficacy of 150 mg and 300 mg of L9LS against P. falciparum infection as detected by blood smear observed after the first malaria season in the original protocol. Specifically, if 150 mg and 300 mg of L9LS both show ≥60% efficacy during the first malaria season (based on the upper bound of the two-sided 95% confidence interval \[CI\]), participants will be re-randomized 1:1 in a double-blind fashion within each arm to receive a single dose of either L9LS (150 or 300 mg depending on study arm) or placebo administered SC before the 2023 malaria season. The same randomization scheme will be followed if in the first malaria season the 300-mg dose of L9LS shows ≥60% efficacy (based on the upper bound of the two-sided 95% CI) and the 150-mg dose of L9LS shows \<60% efficacy (based on the upper bound of the two-sided 95% CI) but the difference between their respective point estimates of efficacy is ≤10%, with the exception that children who received placebo in year 1 will receive 300 mg of L9LS (or placebo) in year 2. If 300 mg of L9LS shows ≥60% efficacy (based on the upper bound of the two-sided 95% CI) and 150 mg of L9LS shows \<60% efficacy (based on the upper bound of the two-sided 95% CI) but the difference between their respective point estimates of efficacy is \>10% during the first malaria season, participants will be re-randomized 1:1 in a double-blind fashion within each arm to receive a single dose of either 300 mg of L9LS or placebo administered SC before the 2023 malaria season. If 150 mg and 300 mg of L9LS both show \<60% efficacy (based on the upper bound of the two-sided 95% CI) after the first malaria season, the protocol extension will be abandoned. Before study agent administration, all subjects will be given artemether-lumefantrine to clear any preexisting Pf blood-stage infection. Subjects will be followed at study visits 1, 3, 7, 14, 21, and 28 days after administration, and once every 2 weeks thereafter through 28 weeks, with a final visit occurring on study day 252 (36 weeks) to collect a final PK sample. Primary study assessments include medical history, physical examination, and blood collection for pharmacokinetics (PK), anti-drug antibody (ADA) assessments, identification of Pf infection by microscopic examination of thick blood smears and RT-PCR, and other research laboratory evaluations.
Interventions
BIOLOGICALL9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection
Administered one time via subcutaneous route.
BIOLOGICALL9LS (VRC-MALMAB0114-00-AB) intravenous injection
Administered one time via intravenous route.
OTHERPlacebo
Normal saline administered one time via subcutaneous route.
Sponsors
National Institutes of Health (NIH)
Malaria Research and Training Center, Bamako, Mali
University of the Sciences, Techniques and Technologies of Bamako
University of Washington
Harvard School of Public Health (HSPH)
Indiana University School of Medicine
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Is within the appropriate age range for the respective cohort: 1. Children: Aged ≥6 years and \<11 years. 2. Adults: Aged ≥18 years. * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. * In good general health and without clinically significant medical history. * Adult participants or parent and/or guardian of minor participants able to provide informed consent. * Willing to have blood samples and data stored for future research. * Resides in or near Kalifabougou or Torodo, Mali, and available for the duration of the study. * For the adult cohort, females of childbearing potential must be willing to use reliable contraception from 21 days prior to study day 0 through the final study visit as described below. * Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device. * Nonchildbearing women will be required to report date of last menstrual period, history of surgical sterility (i.e., tubal ligation, hysterectomy) or premature ovarian insufficiency, and will have urine or serum pregnancy test performed per protocol. Year 2 Extension Inclusion Criteria: * Participated in the first year of the protocol. * Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. * In good general health and without clinically significant medical history. * Parent and/or guardian able to provide informed consent. * Willing to have blood samples and data stored for future research. * Resides in or near Kalifabougou or Torodo, Mali, and available for the duration of the study.
Exclusion criteria
* Body weight \<15 kg or \>30 kg for children, or \>60 kg for adults. * Currently receiving or planning to receive seasonal malaria chemoprevention (SMC). * Any history of menses (for 6-10 year old cohort) or positive pregnancy test at screening (for adult cohort). * Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol. * Subject (for adult subjects) or parental (for minor subjects) study comprehension examination score of \<80% correct or per investigator discretion. * Hemoglobin, white blood cell, absolute neutrophil, or platelet count outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for not clinically significant values.) * Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for not clinically significant values.) * Infected with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV). * Known or documented sickle cell disease by history. (Note: Known sickle cell trait is NOT exclusionary.) * Clinically significant abnormal electrocardiogram (ECG; Corrected QT Interval (QTc) \>460 or other significant abnormal findings, including unexplained tachycardia or bradycardia). * Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis. * Receipt of any investigational product within the past 30 days. * Participation or planned participation in an interventional trial with an investigational product before the last required protocol visit. (Note: Past, current, or planned participation in observational studies is NOT exclusionary.) * Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. * History of a severe allergic reaction or anaphylaxis. * Severe asthma (defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years). * Salivary gland disorder diagnosed by a doctor (e.g., parotitis, sialadenitis, sialolithiasis, salivary gland tumors). * Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia. * Known immunodeficiency syndrome. * Known asplenia or functional asplenia. * Use of chronic (≥14 days) oral or IV corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone \>10 mg/day) or immunosuppressive drugs within 30 days of day 0. * Receipt of a live vaccine within the past 4 weeks or a killed vaccine or COVID-19 vaccine within the past 2 weeks prior to study agent administration. * Receipt of immunoglobulins and/or blood products within the past 6 months. * Previous receipt of an investigational malaria vaccine or monoclonal antibody in the last 5 years. * Known allergies or contraindication against artemether-lumefantrine. * Clinical signs of malnutrition. * Other condition(s) that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or render the subject unable to comply with the protocol. Year 2 Extension
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity of Systemic Adverse Events (AEs) - Year One | Within 7 days after the administration of L9LS | The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death |
| Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study | Day 7 through week 28 | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by microscopic examination of thick blood smear collected from participants from day 14 through week 28 (196 days) after administration of L9LS or placebo. Analysis was done as number of participants who had at least one positive blood smear. |
| Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study | Measured through week 36 | Number of participants with detectable anti-drug antibody (ADA) in sera after exposure to L9LS. Serum was collected from participants at specific timepoints throughout the study, on days 0, 7, 28, 84, 168, and 196. The tier 3 assay was used to directly measure ADA's ability to impair L9LS binding to Plasmodium falciparum circumsporozoite protein (PfCSP). Analysis was done to determine number of participants with positive or detectable ADA in sera. |
| Maximum Total Plasma Concentration (Cmax) for L9LS - Extension Study | Measured through Week 36 | Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, & 252 after the administration of L9LS. Cmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose. Analysis was done to determine each participant's observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations. |
| Time to Maximum Plasma Concentration (TMax) for L9LS - Extension Study | Measured through Week 36 | Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, & 252 after the administration of L9LS. Tmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles. Analysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration. |
| Participants With Local Adverse Events (AEs) - Extension Study | Within 7 days after administration of L9LS | Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants. |
| Severity of Local Adverse Events (AEs) - Extension Study | Within 7 days after administration of L9LS | The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death |
| Participants With Systemic Adverse Events (AEs) - Extension Study | Within 7 days after the administration of L9LS | Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants. |
| Severity of Systemic Adverse Events (AEs) - Extension Study | Within 7 days after the administration of L9LS | The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death |
| Participants With Local Adverse Events (AEs) - Year One | Within 7 days after administration of L9LS | Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants. |
| Severity of Local Adverse Events (AEs) - Year One | Within 7 days after administration of L9LS | The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death |
| Participants With Systemic Adverse Events (AEs) - Year One | Within 7 days after the administration of L9LS | Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study | Measured through Week 28 | Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment. |
| Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study | Measured through Week 24 | Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment. |
| Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One | Measured through Week 36 | Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, & 252 after the administration of L9LS. Cmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose. Analysis was done to determine each participant's observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations. |
| Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One | Measured through Week 36 | Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum was collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, & 252 after administration of L9LS. Tmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles. Analysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration. |
| Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | Measured through week 24 (dose escalation study) and week 28 (efficacy study) | Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood sample positive for Pf was assessed by real-time polymerase chain reaction (RT-PCR) of blood sample collected from participants from day 0 through week 28 (196 days) after administration of L9LS or placebo. Analysis was done as number of participants who had at least one positive blood sample. |
| Participants With Clinical Malaria - Pediatric Dose Escalation Study | Measured through Week 28 | Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia \>5,000 parasites/μL as detected from microscopic examination of thick blood smear. Assessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo. Subjective data, objective data and blood sample were collected from administration of intervention through week 28. Analysis was done as number of participants who had at least one symptom and positive blood sample. |
| Participants With Clinical Malaria - Pediatric Efficacy Study | Measured through Week 28 | Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia \>5,000 parasites/μL as detected from microscopic examination of thick blood smear. Assessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo. Subjective data, objective data and blood sample were collected from administration of intervention through week 28. Analysis was done as number of participants who had at least one symptom and positive blood sample. |
Countries
Mali
Participant flow
Pre-assignment details
365 participants were consented (341 pediatrics, 36 adults): * 62 participants were ineligible (57 pediatrics, five adults) * 23 participants served as backup (22 pediatrics, one adult) * One pediatric participant withdrew consent * 279 participants received intervention (261 pediatrics, 18 adults) in year one * 235 pediatric participants from year one participated in the extension study in year two
Participants by arm
| Arm | Count |
|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS Adult participants receive single dose of 300 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 2.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 6 |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS Adult participants receive single dose of 600 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns dosing begins for arm 3.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 6 |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS Adult participants receive highest single dose of 20 mg/kg IV of L9LS intravenously. Once subjects reach day 7 post-administration without safety concerns dosing begins for pediatric subjects dose escalation arm 1.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via intravenous route. | 6 |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS Pediatric subjects ages 6-10 years receive 150 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for arm 2.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 9 |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS Pediatric subjects ages 6-10 years receive 300 mg of L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for the pediatric efficacy study arms.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 9 |
| Pediatric Dose-escalation Study: Arm 3: Placebo Pediatric subjects ages 6-10 receive placebo of normal saline subcutaneously.
Normal saline: Administered one time via subcutaneous administration. | 18 |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS Pediatric subjects ages 6-10 receive 150 mg of L9LS subcutaneously.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 75 |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS Pediatric subjects ages 6-10 receive 300 mg of L9LS subcutaneously.
L9LS (VRC-MALMAB0114-00-AB): Administered one time via subcutaneous route. | 75 |
| Pediatric Efficacy Study: Arm 3: Placebo Pediatric subjects ages 6-10 receive placebo of normal saline subcutaneously.
Normal saline: Administered one time via subcutaneous administration. | 75 |
| Total | 279 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pediatric Efficacy Study | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Pediatric Efficacy Study | Withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
| Pediatric Extension Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
Baseline characteristics
| Characteristic | Total | Pediatric Efficacy Study: Arm 3: Placebo | Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Pediatric Dose-escalation Study: Arm 3: Placebo | Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Adult Dose-escalation Study: Arm 1: 300 mg of L9LS |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 10 | 33 Participants | 8 Participants | 13 Participants | 6 Participants | 3 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 18-20 | 5 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 3 Participants |
| Age, Customized 21-30 | 5 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 3 Participants | 0 Participants |
| Age, Customized 31-40 | 4 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants |
| Age, Customized 41-50 | 4 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Age, Customized 51-55 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 6 | 80 Participants | 31 Participants | 23 Participants | 20 Participants | 5 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 7 | 39 Participants | 8 Participants | 11 Participants | 11 Participants | 4 Participants | 2 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 8 | 64 Participants | 19 Participants | 13 Participants | 23 Participants | 4 Participants | 2 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Customized 9 | 45 Participants | 9 Participants | 15 Participants | 15 Participants | 2 Participants | 3 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized African | 279 Participants | 75 Participants | 75 Participants | 75 Participants | 18 Participants | 9 Participants | 9 Participants | 6 Participants | 6 Participants | 6 Participants |
| Region of Enrollment Mali | 279 participants | 75 participants | 75 participants | 75 participants | 18 participants | 9 participants | 9 participants | 6 participants | 6 participants | 6 participants |
| Sex: Female, Male Female | 129 Participants | 36 Participants | 33 Participants | 31 Participants | 8 Participants | 3 Participants | 7 Participants | 4 Participants | 4 Participants | 3 Participants |
| Sex: Female, Male Male | 150 Participants | 39 Participants | 42 Participants | 44 Participants | 10 Participants | 6 Participants | 2 Participants | 2 Participants | 2 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 9 | 0 / 9 | 0 / 18 | 0 / 75 | 0 / 75 | 0 / 75 | 0 / 79 | 0 / 38 | 0 / 118 |
| other Total, other adverse events | 5 / 6 | 6 / 6 | 6 / 6 | 9 / 9 | 8 / 9 | 18 / 18 | 67 / 75 | 71 / 75 | 72 / 75 | 74 / 79 | 33 / 38 | 111 / 118 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 9 | 0 / 9 | 0 / 18 | 0 / 75 | 0 / 75 | 0 / 75 | 0 / 79 | 0 / 38 | 0 / 118 |
Outcome results
Primary
Maximum Total Plasma Concentration (Cmax) for L9LS - Extension Study
Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, & 252 after the administration of L9LS. Cmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose. Analysis was done to determine each participant's observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations.
Time frame: Measured through Week 36
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the L9LS intervention during the extension study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Extension Study | 64.63 ug/mL | Standard Deviation 17.36 |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Extension Study | 116.93 ug/mL | Standard Deviation 24.78 |
Primary
Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study
Number of participants with detectable anti-drug antibody (ADA) in sera after exposure to L9LS. Serum was collected from participants at specific timepoints throughout the study, on days 0, 7, 28, 84, 168, and 196. The tier 3 assay was used to directly measure ADA's ability to impair L9LS binding to Plasmodium falciparum circumsporozoite protein (PfCSP). Analysis was done to determine number of participants with positive or detectable ADA in sera.
Time frame: Measured through week 36
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention in the extension study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Detectable Anti-drug Antibody (ADA) in Sera - Extension Study | 0 Participants |
Primary
Participants With Local Adverse Events (AEs) - Extension Study
Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants.
Time frame: Within 7 days after administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Injection site swelling | 1 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Redness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pain at Injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pain at Injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Injection site swelling | 2 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Redness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Injection site swelling | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Pain at Injection site | 1 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Extension Study | Redness at injection site | 0 Participants |
Primary
Participants With Local Adverse Events (AEs) - Year One
Number of participants with local adverse events occurring within 7 days after administration of L9LS. Local reactogenicity included pain/tenderness, swelling, redness, bruising, and pruritus at the site of infusion. Adverse events were captured by Investigator examination and history from participants.
Time frame: Within 7 days after administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 3 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 1 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 1 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 1 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 3 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Pruritus at injection site | 1 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Bruising at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Injection site swelling | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Redness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Tenderness at injection site | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Local Adverse Events (AEs) - Year One | Pain at Injection site | 1 Participants |
Primary
Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study
Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood smear-positive for Pf was assessed by microscopic examination of thick blood smear collected from participants from day 14 through week 28 (196 days) after administration of L9LS or placebo. Analysis was done as number of participants who had at least one positive blood smear.
Time frame: Day 7 through week 28
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention during the efficacy study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study | 36 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study | 30 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Microscopic Examination - Efficacy Study | 61 Participants |
Primary
Participants With Systemic Adverse Events (AEs) - Extension Study
Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants.
Time frame: Within 7 days after the administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Muscle aches | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Fever | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Headache | 1 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Headache | 1 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Fever | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Muscle aches | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Fever | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Headache | 4 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Extension Study | Muscle aches | 0 Participants |
Primary
Participants With Systemic Adverse Events (AEs) - Year One
Number of participants with local adverse events occurring within 7 days after administration of L9LS. Systemic reactogenicity events included fever, feeling unusually tired or unwell, muscle aches, headache, chills, nausea, and joint pain. Adverse events were captured by Investigator examination and history from participants.
Time frame: Within 7 days after the administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 1 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 2 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 3 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 1 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 1 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Fever | 1 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Nausea | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Joint pain | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Feeling unusually tired or unwell | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Chills | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Muscle aches | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Participants With Systemic Adverse Events (AEs) - Year One | Headache | 1 Participants |
Primary
Severity of Local Adverse Events (AEs) - Extension Study
The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death
Time frame: Within 7 days after administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 1 | 1 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 1 | 2 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 1 | 1 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Extension Study | Grade 2 | 0 Participants |
Primary
Severity of Local Adverse Events (AEs) - Year One
The severity of local AEs was graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Clinical Trials. Grade 1: Pain = does not interfere with activity; Tenderness = mild discomfort to touch; Erythema/Redness = 2.5-5 cm; Induration/Swelling = 2.5-5 cm and does not interfere with activity. Grade 2: Pain = Repeated use of non-narcotic pain reliever \> 24 hours or interferes with daily activity; Tenderness= Discomfort with movement; Erythema/Redness = 5.1-10 cm; Induration/Swelling = 5.1-10 cm and interferes with activity. Grade 3: Pain = Any use of narcotic pain reliever or prevents daily activity; Tenderness = Significant discomfort at rest; Erythema/Redness = \> 10 cm; Induration/Swelling = \> 10 cm or prevents daily activity. Grade 4: Pain = Emergency room (ER) visit or hospitalization; Tenderness = ER visit or hospitalization; Erythema/Redness = Necrosis or exfoliative dermatitis; induration/Swelling = Necrosis Grade 5: Death
Time frame: Within 7 days after administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 3 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 1 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 2 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 3 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 1 | 2 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Local Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
Primary
Severity of Systemic Adverse Events (AEs) - Extension Study
The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death
Time frame: Within 7 days after the administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 2 | 1 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 2 | 1 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 1 | 1 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Extension Study | Grade 2 | 3 Participants |
Primary
Severity of Systemic Adverse Events (AEs) - Year One
The severity of systemic AEs occurring after the administration of L9LS was assessed using the grading scale below: Grade 1: Fever = 37.5\^oC-37.9\^oC; Fatigue, Headache, Myalgia = No interference with activity; Nausea = no interference with activity or 1-2 episodes/hour Grade 2: Fever = 38\^oC-38.4\^oC; Fatigue, Myalgia = Some interference with activity; Headache = Repeated use of non-narcotic pain reliever \> 24 hours or some interference with activity; Nausea = Some interference with activity or \> 2 episodes/24 hours Grade 3: Fever = 38.5\^oC-39.5\^oC; Fatigue = Prevents daily activity; Headache =Significant; any use of narcotic pain reliever or prevents daily activity; Myalgia =Significant; prevents daily activity; Nausea = Prevents daily activity, requires outpatient intravenous hydration Grade 4: Fever = \> 39.5\^oC; Fatigue, Headache, Myalgia = Emergency room (ER) visit or hospitalization; Nausea = ER visit or hospitalization for hypotensive shock Grade 5: Death
Time frame: Within 7 days after the administration of L9LS
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 1 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 4 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 1 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 1: 150 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 1 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 2: 300 mg of L9LS | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 1 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 5 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 1 | 2 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 4 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 2 | 0 Participants |
| Pediatric Efficacy Study: Arm 3: Placebo | Severity of Systemic Adverse Events (AEs) - Year One | Grade 3 | 0 Participants |
Primary
Time to Maximum Plasma Concentration (TMax) for L9LS - Extension Study
Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 84, 140, 196, & 252 after the administration of L9LS. Tmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles. Analysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration.
Time frame: Measured through Week 36
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the L9LS intervention during the extension study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Extension Study | 7.00 Days | Standard Deviation 0.16 |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Extension Study | 7.58 Days | Standard Deviation 3.41 |
Secondary
Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One
Maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, & 252 after the administration of L9LS. Cmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles post dose. Analysis was done to determine each participant's observed maximum concentration based on all available timepoints and cumulative output was calculated as the central tendency and dispersion metric based on the observed maximum concentrations.
Time frame: Measured through Week 36
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received L9LS in year one study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One | 76.97 ug/mL | Standard Deviation 18.88 |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One | 142.79 ug/mL | Standard Deviation 30.36 |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One | 76.19 ug/mL | Standard Deviation 22.04 |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Maximum Total Plasma Concentration (Cmax) for L9LS - Study Year One | 142.70 ug/mL | Standard Deviation 29.56 |
Secondary
Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study
Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment.
Time frame: Measured through Week 28
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the intervention during the pediatric dose escalation study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study | 7 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study | 7 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Dose Escalation Study | 13 Participants |
Secondary
Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study
Number of participants with clinical malaria during a single malaria season, defined by an illness accompanied by any level of Plasmodium Falciparum (Pf) asexual parasitemia as detected from microscopic examination of thick blood smear that results in the administration of anti-malarial treatment.
Time frame: Measured through Week 24
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received intervention during the pediatric efficacy study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study | 33 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study | 25 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Clinical Malaria Detected by Microscopic Examination of Thick Blood Smear - Pediatric Efficacy Study | 57 Participants |
Secondary
Participants With Clinical Malaria - Pediatric Dose Escalation Study
Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia \>5,000 parasites/μL as detected from microscopic examination of thick blood smear. Assessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo. Subjective data, objective data and blood sample were collected from administration of intervention through week 28. Analysis was done as number of participants who had at least one symptom and positive blood sample.
Time frame: Measured through Week 28
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received intervention during the pediatric dose escalation study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Clinical Malaria - Pediatric Dose Escalation Study | 6 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Clinical Malaria - Pediatric Dose Escalation Study | 4 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Clinical Malaria - Pediatric Dose Escalation Study | 11 Participants |
Secondary
Participants With Clinical Malaria - Pediatric Efficacy Study
Number of pediatric participants with clinical malaria during a single malaria season, defined by an illness accompanied by measured axillary fever ≥37.5°C, or history of fever (subjective or objective) in the previous 24 hours, and Plasmodium falciparum (Pf) asexual parasitemia \>5,000 parasites/μL as detected from microscopic examination of thick blood smear. Assessment was done from day 0 through week 28 (196 days) after administration of L9LS or placebo. Subjective data, objective data and blood sample were collected from administration of intervention through week 28. Analysis was done as number of participants who had at least one symptom and positive blood sample.
Time frame: Measured through Week 28
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received the study intervention.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Clinical Malaria - Pediatric Efficacy Study | 21 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Clinical Malaria - Pediatric Efficacy Study | 14 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Clinical Malaria - Pediatric Efficacy Study | 44 Participants |
Secondary
Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR)
Number of participants with Plasmodium falciparum (Pf) blood stage infection defined as blood sample positive for Pf was assessed by real-time polymerase chain reaction (RT-PCR) of blood sample collected from participants from day 0 through week 28 (196 days) after administration of L9LS or placebo. Analysis was done as number of participants who had at least one positive blood sample.
Time frame: Measured through week 24 (dose escalation study) and week 28 (efficacy study)
Population: Modified intention-to-treat (MITT) - Analysis include all randomized pediatric subjects that received intervention during year one of the study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 7 Participants |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 8 Participants |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 13 Participants |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 33 Participants |
| Pediatric Dose-escalation Study: Arm 2: 300 mg of L9LS | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 32 Participants |
| Pediatric Dose-escalation Study: Arm 3: Placebo | Participants With Plasmodium Falciparum (Pf) Infection Detected by Real-Time Polymerase Chain Reaction (RT-PCR) | 62 Participants |
Secondary
Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One
Time to maximum total plasma concentration (Cmax) following a dose of 150 mg or 300 mg L9LS. Serum was collected on days 0, 7, 28, 56, 84, 112, 140, 168, 196, 224, & 252 after administration of L9LS. Tmax for L9LS was obtained directly by visual inspection of the plasma concentration versus time profiles. Analysis was done to determine the time (in days) at which the maximum observed concentration was achieved for each participant and cumulative output was calculated as the central tendency and dispersion metric based on the observed time of maximum concentration.
Time frame: Measured through Week 36
Population: Modified intention-to-treat (MITT) - Analysis include all randomized subjects that received L9LS in year one study.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Adult Dose-escalation Study: Arm 1: 300 mg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One | 7.00 Days | Standard Deviation 0 |
| Adult Dose-escalation Study: Arm 2: 600 mg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One | 7.00 Days | Standard Deviation 0 |
| Adult Dose-escalation Study: Arm 3: 20 mg/kg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One | 7.17 Days | Standard Deviation 2.46 |
| Pediatric Dose-escalation Study: Arm 1: 150 mg of L9LS | Time to Maximum Plasma Concentration (TMax) for L9LS - Study Year One | 7.36 Days | Standard Deviation 2.45 |